Cardiovascular disease: much more aggressive in patients with type 2 diabetes.

被引:25
|
作者
Chiquette E. [1 ]
Chilton R. [1 ]
机构
[1] University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, 78284-7872, TX
关键词
Coronary Artery Bypass Graft; Pravastatin; United Kingdom Prospective Diabetes Study; Left Internal Mammary Artery; Silent Ischemia;
D O I
10.1007/s11883-002-0037-z
中图分类号
学科分类号
摘要
It is estimated that 80% of individuals with type 2 diabetes die of coronary heart disease. Several factors have been found to contribute to the accelerated atherosclerosis present in diabetic patients. These include hyperglycemia-induced endothelial cell dysfunction, impaired fibrinolysis, increased platelet aggregation, and dysfunctional arterial remodeling. The evidence supports that a healthy lifestyle, statin drugs, angiotensin-converting enzyme inhibitors, and aspirin can modify these factors and slow the atherosclerosis process observed in type 2 diabetes. Because of the high prevalence of cardiovascular disease in people with type 2 diabetes, early cardiac testing is indicated. The optimal strategy for coronary revascularization in diabetic patients remains controversial and is discussed in detail in this review.
引用
收藏
页码:134 / 142
页数:8
相关论文
共 50 条
  • [21] Predictors of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus
    Tan, M. C.
    Wong, T. W.
    Chan, Y. M.
    Joseph, A.
    Hejar, A. R.
    Ng, O. C.
    INTERNATIONAL JOURNAL OF COLLABORATIVE RESEARCH ON INTERNAL MEDICINE & PUBLIC HEALTH, 2013, 5 (07) : 492 - 506
  • [22] Prevalence of CKD in Patients with Type 2 Diabetes and Cardiovascular Disease
    Yang, J.
    Lu, R.
    Wang, Y.
    Ke, J.
    Huang, W.
    Lu, Q.
    Zhao, D.
    Liu, G.
    Gao, H.
    Hong, T.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
  • [23] Glycemic variability and cardiovascular disease in patients with type 2 diabetes
    Martinez, Marcela
    Santamarina, Jimena
    Pavesi, Adrian
    Musso, Carla
    Umpierrez, Guillermo E.
    BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [24] Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus
    Fujihara, Kazuya
    Sone, Hirohito
    ANNALS OF VASCULAR DISEASES, 2018, 11 (01) : 2 - 14
  • [25] Plasma metals and cardiovascular disease in patients with type 2 diabetes
    Long, Tengfei
    Wang, Ruixin
    Wang, Jing
    Wang, Fei
    Xu, Yali
    Wei, Yue
    Zhou, Lue
    Zhang, Xiaomin
    Yuan, Jing
    Yao, Ping
    Wei, Sheng
    Guo, Huan
    Yang, Handong
    Wu, Tangchun
    He, Meian
    ENVIRONMENT INTERNATIONAL, 2019, 129 : 497 - 506
  • [26] Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
    Gaede, P
    Vedel, P
    Larsen, N
    Jensen, GVH
    Parving, H
    Pedersen, O
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (05): : 383 - 393
  • [27] Protein oxidation and cardiovascular disease in patients with type 2 diabetes
    Bryk, A. H.
    Konieczynska, M.
    Broniatowska, E.
    Undas, A.
    EUROPEAN HEART JOURNAL, 2018, 39 : 905 - 905
  • [28] Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes.
    Huerta M.G.
    Nadler J.L.
    Current Diabetes Reports, 2002, 2 (5) : 396 - 402
  • [29] Insulin treatment in type 2 diabetes. More opportunities than risks
    Stulnig, T.
    DIABETOLOGE, 2014, 10 (06): : 460 - 465
  • [30] Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
    Fitchett, David
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    van de Borne, Philippe
    Mattheus, Michaela
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    George, Jyothis T.
    Zinman, Bernard
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (03) : 364 - 367